Lytix Biopharma Announces Approval by Hungarian Authorities and Ethics Committee to Start Phase IIa Clinical Trial with LytixarTM (LTX-109) in Gram Positive Skin Infections

TROMSØ & OSLO, Norway--(BUSINESS WIRE)--The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval in Hungary to commence a Phase IIa clinical trial with LytixarTM (LTX-109) treatment of skin infections caused by Gram positive bacteria.